Systemic therapy for hepatocellular carcinoma: beyond sorafenib

Area of Science:

• Hepatology and Oncology
• Translational Cancer Research

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally and in the US.
• Sorafenib, the first FDA-approved first-line systemic treatment for HCC, offers limited survival benefits and significant side effects.

Purpose of the Study:

• To review systemic treatments for incurable HCC beyond sorafenib.
• To highlight advancements in kinase inhibitors, immunotherapies, and combination therapies for HCC.

Main Methods:

• Literature review of systemic treatments for advanced HCC.
• Analysis of recent clinical trial data and research publications.

Main Results:

• Emerging kinase inhibitors show promise in targeting specific HCC pathways.
• Immunotherapies, particularly checkpoint inhibitors, demonstrate significant efficacy in select HCC patient populations.
• Combination therapies are being investigated to enhance treatment outcomes.

Conclusions:

• Systemic treatment options for advanced HCC have expanded significantly beyond sorafenib.
• Targeted therapies and immunotherapies represent key advancements in HCC management.
• Further research into combination strategies is crucial for improving patient survival and quality of life.